Y
Yang Lin
Publications - 4
Citations - 9484
Yang Lin is an academic researcher. The author has contributed to research in topics: Pharmacokinetics & Adverse effect. The author has an hindex of 2, co-authored 2 publications receiving 7256 citations.
Papers
More filters
Journal ArticleDOI
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Roujian Lu,Xiang Zhao,Juan Li,Peihua Niu,Bo Yang,Honglong Wu,Wenling Wang,Hao Song,Baoying Huang,Na Zhu,Yuhai Bi,Xuejun Ma,Faxian Zhan,Liang Wang,Tao Hu,Hong Zhou,Zhenhong Hu,Weimin Zhou,Li Zhao,Jing Chen,Yao Meng,Ji Wang,Yang Lin,Jianying Yuan,Zhihao Xie,Jinmin Ma,William J. Liu,Dayan Wang,Wenbo Xu,Edward C. Holmes,George F. Gao,George F. Gao,Guizhen Wu,Weijun Chen,Weifeng Shi,Wenjie Tan,Wenjie Tan +36 more
TL;DR: The phylogenetic analysis suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.
Posted ContentDOI
Effect of large-scale testing platform in prevention and control of the COVID-19 pandemic: an empirical study with a novel numerical model
Qing Xie,Jing Wang,Jianling You,Shida Zhu,Rui Zhou,Zhijian Tian,Hao Wu,Yang Lin,Wei Chen,Lan Xiao,Xin Jin,Jianjuan Li,Jie Dong,Honglong Wu,Wei Zhang,Jing Li,Xun Xu,Ye Yin,Feng Mu,Weijun Chen,Jian Wang +20 more
TL;DR: Large-scale and standardized clinical testing platform with nucleic acid testing, high-throughput sequencing and immunoprotein assessment capabilities need to be implemented simultaneously in order to maximize the effect of quarantine and minimize the duration and cost.
Journal ArticleDOI
The randomized, single‐ and multiple‐ ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects
TL;DR: In this article , the authors evaluated the pharmacokinetics (PKs), safety, and tolerability of single and multiple ascending doses of CSPCHA115 in Chinese healthy subjects, using a randomized, double-blind, placebo-controlled, single center, and ascending-dose design.
Journal ArticleDOI
A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects
TL;DR: In this paper , the authors investigated the single and multiple-dose pharmacokinetics of perampanel in healthy Chinese adults in a phase I, single-center, open-label, parallel-group study.